FASLG and cholangiocarcinoma: Shimonishi et al. further demonstrated upregulation of FASL in the early stages and downregulation of FAS in the advanced stages of cholangiocarcinoma, the latter of which was responsible for evasion from host immunity and disease progression (Shimonishi et al., 2000).